New imaging agent could sharpen prostate cancer staging

NCT ID NCT06122584

Recruiting now Diagnosis Sponsor: ABX advanced biochemical compounds GmbH Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial is testing whether a radioactive tracer called [18F]PSMA-1007 can improve PET/CT scans for men with newly diagnosed high-risk or very-high-risk prostate cancer. The goal is to see if it can more accurately detect cancer that has spread to pelvic lymph nodes. About 380 men will receive the tracer before undergoing prostate removal surgery, and the scan results will be compared with tissue samples.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [18F]PSMA-1007 (a radioactive tracer for PET scans)
What this could lead to: If successful, this could provide a more accurate way to detect cancer spread in lymph nodes, helping doctors plan better treatment for high-risk prostate cancer.
What could go wrong: This is a diagnostic study, not a treatment. The tracer may not prove more accurate than current methods, and results depend on comparison with surgical tissue samples.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

CHRU de Nancy
RECRUITING

Nancy, France
CWZ
RECRUITING

Nijmegen, Netherlands
Carl Gustav Carus Faculty of Medicine, TUD Dresden
RECRUITING

Dresden, Germany
Hospital Del Mar
RECRUITING

Barcelona, Spain
Hospital Vall d'Hebron
RECRUITING

Barcelona, Spain
Hospital Vithas Valencia 9 de Octubre
ACTIVE_NOT_RECRUITING

Valencia, Spain
IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
RECRUITING

Meldola, Italy
IRCCS Ospedale Sacro Cuore-Don Calabria
RECRUITING

Verona, Italy
Klinikum rechts der Isar, TUM
ACTIVE_NOT_RECRUITING

München, Germany
National Cancer Center
RECRUITING

Tokyo, Japan
Radboud UMC
RECRUITING

Nijmegen, Netherlands
St. Antonius Hospital
RECRUITING

Gronau, Germany
The University of Osaka Hospital
RECRUITING

Osaka, Japan
University Hospital Düsseldorf
RECRUITING

Düsseldorf, Germany
University Hospital Hamburg-Eppendorf
RECRUITING

Hamburg, Germany
University Hospital Leipzig
RECRUITING

Leipzig, Germany
University Hospital Münster
RECRUITING

Münster, Germany
Universitätsmedizin Rostock
RECRUITING

Rostock, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.